FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2267367070> ?p ?o ?g. }

• W2267367070 endingPage "353" @default.
• W2267367070 startingPage "345" @default.
• W2267367070 abstract "The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade 3-4 drug-related toxicity to ipilimumab. We report long-term survival, response duration, and biomarkers in these patients after nivolumab treatment (3 mg/kg) every 2 weeks for 24 weeks, then every 12 weeks for up to 2 years, with or without a multipeptide vaccine. The response rate for ipilimumab-refractory patients was 30% (95% CI, 21%-41%). The median duration of response was 14.6 months, median progression-free survival was 5.3 months, and median overall survival was 20.6 months, when patients were followed up for a median of 16 months. One- and 2-year survival rates were 68.4% and 31.2%, respectively. Ipilimumab-naïve and ipilimumab-refractory patients showed no significant difference in survival. The 21 patients with prior grade 3-4 toxicity to ipilimumab that was managed with steroids tolerated nivolumab well, with 62% (95% CI, 38%-82%) having complete or partial responses or stabilized disease at 24 weeks. High numbers of myeloid-derived suppressor cells (MDSC) were associated with poor survival. Thus, survival and long-term safety were excellent in ipilimumab-refractory patients treated with nivolumab. Prior grade 3-4 immune-related adverse effects from ipilimumab were not indicative of nivolumab toxicities, and patients had a high overall rate of remission or stability at 24 weeks. Prospectively evaluating MDSC numbers before treatment could help assess the expected benefit of nivolumab." @default.
• W2267367070 created "2016-06-24" @default.
• W2267367070 creator A5003092267 @default.
• W2267367070 creator A5006097304 @default.
• W2267367070 creator A5012911914 @default.
• W2267367070 creator A5014833866 @default.
• W2267367070 creator A5023605565 @default.
• W2267367070 creator A5026672076 @default.
• W2267367070 creator A5027960464 @default.
• W2267367070 creator A5052521597 @default.
• W2267367070 creator A5055925608 @default.
• W2267367070 creator A5062103438 @default.
• W2267367070 creator A5063611038 @default.
• W2267367070 creator A5067274155 @default.
• W2267367070 creator A5068571006 @default.
• W2267367070 creator A5091860403 @default.
• W2267367070 date "2016-03-31" @default.
• W2267367070 modified "2023-10-02" @default.
• W2267367070 title "Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab" @default.
• W2267367070 cites W1567450894 @default.
• W2267367070 cites W1982488143 @default.
• W2267367070 cites W2010121426 @default.
• W2267367070 cites W2039123767 @default.
• W2267367070 cites W2055901890 @default.
• W2267367070 cites W2057893793 @default.
• W2267367070 cites W2060672294 @default.
• W2267367070 cites W2075326745 @default.
• W2267367070 cites W2080886891 @default.
• W2267367070 cites W2099432296 @default.
• W2267367070 cites W2100158834 @default.
• W2267367070 cites W2106511606 @default.
• W2267367070 cites W2107484016 @default.
• W2267367070 cites W2109485845 @default.
• W2267367070 cites W2112121482 @default.
• W2267367070 cites W2118982164 @default.
• W2267367070 cites W2125112000 @default.
• W2267367070 cites W2125616358 @default.
• W2267367070 cites W2128035403 @default.
• W2267367070 cites W2128758225 @default.
• W2267367070 cites W2130066229 @default.
• W2267367070 cites W2135707184 @default.
• W2267367070 cites W2143163879 @default.
• W2267367070 cites W2143488876 @default.
• W2267367070 cites W2146437446 @default.
• W2267367070 cites W2147621820 @default.
• W2267367070 cites W2150048477 @default.
• W2267367070 cites W2151957163 @default.
• W2267367070 cites W2160834915 @default.
• W2267367070 cites W2166662937 @default.
• W2267367070 cites W2179179825 @default.
• W2267367070 cites W2317575649 @default.
• W2267367070 cites W2560367415 @default.
• W2267367070 cites W2572174216 @default.
• W2267367070 cites W2605154526 @default.
• W2267367070 cites W4243065089 @default.
• W2267367070 doi "https://doi.org/10.1158/2326-6066.cir-15-0193" @default.
• W2267367070 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4818672" @default.
• W2267367070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26873574" @default.
• W2267367070 hasPublicationYear "2016" @default.
• W2267367070 type Work @default.
• W2267367070 sameAs 2267367070 @default.
• W2267367070 citedByCount "200" @default.
• W2267367070 countsByYear W22673670702016 @default.
• W2267367070 countsByYear W22673670702017 @default.
• W2267367070 countsByYear W22673670702018 @default.
• W2267367070 countsByYear W22673670702019 @default.
• W2267367070 countsByYear W22673670702020 @default.
• W2267367070 countsByYear W22673670702021 @default.
• W2267367070 countsByYear W22673670702022 @default.
• W2267367070 countsByYear W22673670702023 @default.
• W2267367070 crossrefType "journal-article" @default.
• W2267367070 hasAuthorship W2267367070A5003092267 @default.
• W2267367070 hasAuthorship W2267367070A5006097304 @default.
• W2267367070 hasAuthorship W2267367070A5012911914 @default.
• W2267367070 hasAuthorship W2267367070A5014833866 @default.
• W2267367070 hasAuthorship W2267367070A5023605565 @default.
• W2267367070 hasAuthorship W2267367070A5026672076 @default.
• W2267367070 hasAuthorship W2267367070A5027960464 @default.
• W2267367070 hasAuthorship W2267367070A5052521597 @default.
• W2267367070 hasAuthorship W2267367070A5055925608 @default.
• W2267367070 hasAuthorship W2267367070A5062103438 @default.
• W2267367070 hasAuthorship W2267367070A5063611038 @default.
• W2267367070 hasAuthorship W2267367070A5067274155 @default.
• W2267367070 hasAuthorship W2267367070A5068571006 @default.
• W2267367070 hasAuthorship W2267367070A5091860403 @default.
• W2267367070 hasBestOaLocation W22673670701 @default.
• W2267367070 hasConcept C121332964 @default.
• W2267367070 hasConcept C121608353 @default.
• W2267367070 hasConcept C126322002 @default.
• W2267367070 hasConcept C141071460 @default.
• W2267367070 hasConcept C142424586 @default.
• W2267367070 hasConcept C143998085 @default.
• W2267367070 hasConcept C197934379 @default.
• W2267367070 hasConcept C2777658100 @default.
• W2267367070 hasConcept C2777701055 @default.
• W2267367070 hasConcept C2780030458 @default.
• W2267367070 hasConcept C2781433595 @default.
• W2267367070 hasConcept C502942594 @default.

• next